Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic

Abstract

Patients with various inflammatory diseases of the gastrointestinal tract, skin, liver, kidneys, and musculoskeletal system-connective tissues, often undergo different anti-inflammatory therapies to maintain remission and avoid serious and/or life-threatening complications. Available data so far show an increased rate of hospitalization in such patients during the COVID19 pandemic. The key points of our position statement are summarized below: • Patients with inflammatory diseases who receive moderate or high-risk anti-inflammatory therapies might be considered as an increased risk group for severe COVID-19 and appropriate measures should be taken in order to protect them. • Initiation of immuno-suppressive/modulatory therapies should be done with caution, taking into account the severity of the underlying inflammatory disease, the type of anti-inflammatory and the risk of exposure to the SARS-CoV-2 virus. • Discontinuation of anti-inflammatory therapies in patients who have not been exposed to or infected with the SARS-CoV-2 virus is not recommended. patients who become infected with SARS-CoV-2, anti-inflammatory therapies should be discontinued, except in special cases. • Specialty physicians should actively participate in the Interdisciplinary Teams caring for patients with inflammatory diseases during COVID19